Merve Aslan

Merve Aslan

Auto-generated profile, based on publicly available information

Merve Aslan

Biophysics Graduate Group, University of California, Berkeley, Berkeley, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EHEn-Chi Hsu
En-Chi Hsu
MSMichelle Shen
Michelle Shen
MAMerve Aslan
Merve Aslan
SLShiqin Liu
Shiqin Liu
MKManoj Kumar
Manoj Kumar
TSTanya Stoyanova
Tanya Stoyanova
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and loss of androgen receptor (AR), making it resistant to current therapeutic strategies targeting the AR signaling axis. Here, we report that MCM2, MCM3, MCM4, and MCM6 (MCM2/3/4/6) are elevated in human NEPC and high levels of MCM2/3/4/6 are associated with liver metastasis and poor survival in prostate cancer patients. MCM2/3/4/6 are four out of six proteins that form a core DNA helicase (MCM2-7) responsible for unwinding DNA forks during DNA replication. Inhibition of MCM2-7 by treatment with ciprofloxacin inhibits NEPC cell proliferation and migration in vitro, significantly delays NEPC tumor xenograft growth, and partially reverses the neuroendocrine phenotype in vivo. Our study reveals the clinical relevance of MCM2/3/4/6 proteins in NEPC and suggests that inhibition of MCM2-7 may represent a new therapeutic strategy for NEPC.

5 September 2025 in Cancer Research
Verified
Journal Article
Closed access
SLShiqin Liu
Shiqin Liu
EHEn-Chi Hsu
En-Chi Hsu
MAMerve Aslan
Merve Aslan
FGFernando García-Marqués
Fernando García-Marqués
MSMichelle Shen
Michelle Shen
TSTanya Stoyanova
Tanya Stoyanova
Metastasis is the main cause of prostate cancer–associated deaths, highlighting the urgent need to determine the mechanisms underlying prostate cancer progression. TROP2 (also known as tumor-associated calcium signal transducer 2) is an oncogenic transmembrane surface protein that is highly expressed in metastatic prostate cancer. Naturally occurring cleavage of TROP2 leads to a release of the TROP2 extracellular domain (TECD) into the extracellular environment. In this study, we identified an important functional role of TECD in prostate cancer metastasis. TECD was detectable in media from prostate cancer cells and serum from patients with clinically significant prostate cancer. Although shed TECD did not affect prostate cancer cell proliferation and tumor growth, it increased cell migration and invasion in vitro and promoted metastatic colonization and spontaneous metastasis in vivo. TECD interactome and proteomic studies revealed that TECD binds to EGFR and shed TECD modulates a set of proteins associated with invasion, migration, mTOR signaling, and epithelial-to-mesenchymal transition. Furthermore, elevated shed TECD increased EGFR phosphorylation, resulting in the activation of the EGFR–PI3K–AKT–mTOR pathway in prostate cancer. EGFR inhibitors suppressed the invasive ability of prostate cancer cells driven by TECD overexpression, further supporting the key role of EGFR in TECD-mediated prostate cancer progression. This study uncovers a function of TECD in driving prostate cancer progression and provides mechanistic insights into TECD signaling through EGFR. Significance: Shed extracellular domain of TROP2 binds to and activates EGFR and stimulates the PI3K-AKT-mTOR signaling cascade to promote prostate cancer metastasis, providing potential biomarkers and therapeutic targets.

16 March 2026 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MAMerve Aslan
Merve Aslan
EDEnnio A. D’AMico
Ennio A. D’AMico
NCNathan H. Cho
Nathan H. Cho
ATAryan Taheri
Aryan Taheri
JPJuan M. Perez-Bertoldi
Juan M. Perez-Bertoldi
AYAhmet Yildiz
Ahmet Yildiz

1 December 2025
Verified
Other
Open access
SLShiqin Liu
Shiqin Liu
EHEn-Chi Hsu
En-Chi Hsu
MAMerve Aslan
Merve Aslan
FGFernando García-Marqués
Fernando García-Marqués
MSMichelle Shen
Michelle Shen
TSTanya Stoyanova
Tanya Stoyanova
Metastasis is the main cause of prostate cancer–associated deaths, highlighting the urgent need to determine the mechanisms underlying prostate cancer progression. TROP2 (also known as tumor-associated calcium signal transducer 2) is an oncogenic transmembrane surface protein that is highly expressed in metastatic prostate cancer. Naturally occurring cleavage of TROP2 leads to a release of the TROP2 extracellular domain (TECD) into the extracellular environment. In this study, we identified an important functional role of TECD in prostate cancer metastasis. TECD was detectable in media from prostate cancer cells and serum from patients with clinically significant prostate cancer. Although shed TECD did not affect prostate cancer cell proliferation and tumor growth, it increased cell migration and invasion in vitro and promoted metastatic colonization and spontaneous metastasis in vivo. TECD interactome and proteomic studies revealed that TECD binds to EGFR and shed TECD modulates a set of proteins associated with invasion, migration, mTOR signaling, and epithelial-to-mesenchymal transition. Furthermore, elevated shed TECD increased EGFR phosphorylation, resulting in the activation of the EGFR–PI3K–AKT–mTOR pathway in prostate cancer. EGFR inhibitors suppressed the invasive ability of prostate cancer cells driven by TECD overexpression, further supporting the key role of EGFR in TECD-mediated prostate cancer progression. This study uncovers a function of TECD in driving prostate cancer progression and provides mechanistic insights into TECD signaling through EGFR.Significance:Shed extracellular domain of TROP2 binds to and activates EGFR and stimulates the PI3K-AKT-mTOR signaling cascade to promote prostate cancer metastasis, providing potential biomarkers and therapeutic targets.

1 December 2025
Verified
Other
Open access
PDF file
SLShiqin Liu
Shiqin Liu
EHEn-Chi Hsu
En-Chi Hsu
MAMerve Aslan
Merve Aslan
FGFernando García-Marqués
Fernando García-Marqués
MSMichelle Shen
Michelle Shen
TSTanya Stoyanova
Tanya Stoyanova
Supplementary Figure S3 shows that overexpression of secreted TECD increases migration and invasion ability.

1 December 2025
Verified
Other
Open access
PDF file
SLShiqin Liu
Shiqin Liu
EHEn-Chi Hsu
En-Chi Hsu
MAMerve Aslan
Merve Aslan
FGFernando García-Marqués
Fernando García-Marqués
MSMichelle Shen
Michelle Shen
TSTanya Stoyanova
Tanya Stoyanova
Supplementary Figure S1 shows that Shed TECD is detected in the serum of patients with advanced and clinically significant prostate cancer.